Income statement, balance sheet and cash flow statement for the last 2 fiscal years, taken from the XBRL data Nexscient, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2024
FY2025
Revenue
0
0
Research and development
0.21
0.1
General and administrative
0.73
0.39
Operating expenses
0.94
0.49
Operating income
-0.94
-0.49
Interest expense
0
0.04
Other non-operating income
0
-0.04
Pre-tax income
-0.94
-0.53
Income tax
0
0
Net income
-0.94
-0.53
EBITDA
-0.94
-0.47
EPS, diluted
-0.05
-0.03
Shares, diluted (weighted)
20
20.7
Balance sheet
FY2024
FY2025
Cash and equivalents
0.08
0.1
Other current assets
0.02
0.06
Total current assets
0.1
0.16
Property, plant and equipment
0
Lease right-of-use assets
0.02
0.01
Total assets
0.12
0.3
Accounts payable
0.02
0.02
Accrued liabilities
0
0.04
Total current liabilities
0.04
0.06
Lease liabilities
0.01
0
Total liabilities
0.04
0.57
Paid-in capital
1.09
1.28
Retained earnings
-1.03
-1.56
Shareholders' equity
0.08
-0.26
Total equity
0.08
-0.26
Total liabilities and equity
0.12
0.3
Shares outstanding
20.4
21.3
Cash flow statement
FY2024
FY2025
Net income
-0.94
-0.53
Depreciation and amortization
0
0.02
Stock-based compensation
0.3
0.04
Change in payables
-0.01
-0
Cash from operations
-0.65
-0.41
Cash from investing
0
-0.05
Stock issued
0.52
0
Cash from financing
0.52
0.48
Net change in cash
-0.13
0.02
Interest paid
0
0
Income taxes paid
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.52 on October 2, 2026.
Profitability
Metric
Value
How it is calculated
Net margin
-78.7%
Net income / revenue.
Return on equity (ROE)
-93.1%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-35.1%
Net income / average total assets.
R&D / revenue
4.6%
Research and development expense / revenue.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-423.5%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
142.5%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
3.3%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.73x
Current assets / current liabilities.
Quick ratio
0.55x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.28x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.14x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
6.3%
Total debt / total assets.
Liabilities / assets
54.2%
Total liabilities / total assets.
Net debt
-$192.5K
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.03
Revenue / diluted weighted shares.
Book value per share
$0.06
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
16.2x
Market cap / revenue.
P/B
8.38x
Market cap / shareholders' equity. Only when equity is positive.
EV/Sales
16.0x
Enterprise value / revenue.
Earnings yield
-4.9%
Net income / market cap (the inverse of P/E).
What was Nexscient, Inc.'s revenue in fiscal 2025?
Nexscient, Inc. reported revenue of $0.0 for fiscal 2025.
Was Nexscient, Inc. profitable in fiscal 2025?
No. It reported a net loss of $529.7K.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.